Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.

ABSTRACT:

Importance

Clostridioides difficile infection (CDI) is associated with substantial morbidity and mortality, and recurrent CDI (rCDI) is common.

Objective

To determine whether a 4-week vancomycin pulse and taper regimen would be superior to a standard 2-week vancomycin pulse regimen in terms of recurrence.

Design, setting, and participants

This parallel-design, double-blind clinical trial was performed at 12 Canadian hospitals. Adults with a first episode or first recurrence of CDI were eligible to participate. Patients needed to have clinical CDI with laboratory confirmation and to have improved by day 10 of treatment. Recruitment began November 19, 2020, and all follow-up was completed by October 4, 2024.

Intervention

All patients received a 2-week pulse of va

SUBMITTER: McDonald EG 

PROVIDER: S-EPMC12949445 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature